Your session is about to expire
← Back to Search
AZD9977 for Chronic Kidney Disease (MIRACLE Trial)
MIRACLE Trial Summary
This trial will compare the effect of a new drug, AZD9977, when used with dapagliflozin, to dapagliflozin used alone, in people with heart failure and chronic kidney disease. The trial will also look at different doses of AZD9977 to see what effect it has.
- Chronic Kidney Disease
- Heart Failure
MIRACLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MIRACLE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have Type 1 diabetes.You have a history of dangerous heart rhythm problems or uncontrolled rapid heart rate if you have atrial fibrillation or atrial flutter.You have had a stroke, mini-stroke, or surgery on your carotid artery within the past 3 months.You have taken a certain type of medication called a mineralocorticoid receptor antagonist within the last 90 days.Your body weight is not extremely high for your height.You have had an allergic reaction or sensitivity to a medication called SGLT2 inhibitor, like dapagliflozin or empagliflozin.You have a condition called high output heart failure, which can be caused by conditions like hyperthyroidism or Paget's disease.You have a heart condition that causes slow or irregular heartbeats, and you are not using a pacemaker to help regulate your heart.
- Group 1: AZD9977 Dose C + dapagliflozin 10 mg
- Group 2: Dapagliflozin 10 mg
- Group 3: AZD9977 Dose A + dapagliflozin 10 mg
- Group 4: AZD9977 Dose B + dapagliflozin 10 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current population enrolled in this research project?
"Affirmative. Clinicaltrials.gov indicates that this trial, first posted on January 26th 2021, is in the process of recruiting individuals to participate. Altogether, 500 patients must be found from 33 distinct sites for successful completion of the study."
Are there any vacant slots remaining in this trial for participants?
"Clinicaltrials.gov confirms that this clinical trial is in the process of recruiting participants, with a post date of January 26th 2021 and an edit on November 22nd 2022."
Has Dapagliflozin been explored by other researchers in the past?
"The University of Texas Health Science Center at San Antonio initially conducted research on dapagliflozin in 2014. Presently, there are 18460 completed trials and 63 active ones taking place primarily around Poughkeepsie, New york."
Is this a pioneering endeavor in its respective field?
"As of today, Dapagliflozin is a N/A approved drug after its first clinical trial in 2014. Sponsored by AstraZeneca and involving 700 individuals, it has since been studied extensively with 63 active trials conducted across 235 cities and 50 nations."
Is this research enrolled individuals of advanced age?
"The requirements for this study indicate that suitable candidates must be aged between 21 and 130. Additionally, there are 68 studies available to those under 18 while 1191 exist specifically tailored towards participants above 65 years of age."
Is enrollment currently open to join this research trial?
"Admission to this study requires individuals of ages between 21 and 130 years old that are suffering from cardiac failure. Aspiring participants must be cognizant that 500 spots are available in total."
What ailments does Dapagliflozin typically ameliorate?
"Dapagliflozin is frequently prescribed to treat pharmaceutical preparations, but it can also provide benefits for patients with diet-related issues, an exercise regimen that does not yield the desired results, and those who do not respond well to single therapy."
Does Dapagliflozin exhibit any potentially dangerous side effects?
"While the efficacy of Dapagliflozin is still uncertain, clinical data does suggest safety, so our team at Power gave it a score of 2."
How many health facilities are currently administering this trial in the state?
"At present, 33 medical centres are actively recruiting for this clinical trial. Prospective patients can select from a variety of locations including Poughkeepsie, New Bern and Augusta - to name but a few. It is important to choose the closest site in order to decrease travel requirements if you decide to partake in the study."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger